ライフサイエンスコーパス: insomnia

1 d a severe treatment-emergent adverse event (insomnia).

2 ntly associated with lower odds of prevalent insomnia.

3 t baseline, including depression, mania, and insomnia.

4 patients, especially in patients with severe insomnia.

5 at beta activity in the BG may contribute to insomnia.

6 exploited toward novel treatment targets for insomnia.

7 SRS was greater in patients with more severe insomnia.

8 ed older adults, especially older males with insomnia.

9 diazepine that is prescribed to treat severe insomnia.

10 model for sleep restriction therapy (SRT) of insomnia.

11 and over half screened positive for clinical insomnia.

12 sychiatric disorders that may be linked with insomnia.

13 ng and alcohol drinking were associated with insomnia.

14 ntailored and fixed online information about insomnia.

15 the high prevalence of sleep disorders like insomnia.

16 Scheinker syndrome (GSS), and fatal familial insomnia.

17 he gold standard for behavioral treatment of insomnia.

18 ussler-Scheinker syndrome and fatal familial insomnia.

19 oven in a representative sample with chronic insomnia.

20 roduce clinically meaningful improvements in insomnia.

21 eases suicidality because of improvements in insomnia.

22 ation of effective behavioral treatments for insomnia.

23 se effects were rash, pruritus, fatigue, and insomnia.

24 orexin receptor antagonist for treatment of insomnia.

25 ents included fatigue, headache, nausea, and insomnia.

26 ep, whereas reductions in excitability cause insomnia.

27 ars) and elderly (>/=65 years) patients with insomnia.

28 ts were fatigue, headache, nausea, rash, and insomnia.

29 ator, is the gold-standard drug for treating insomnia.

30 atment for patients with chronic intractable insomnia.

31 es were used to identify 3,135 patients with insomnia.

32 association between carbohydrate intake and insomnia.

33 generational families with combined ADHD and insomnia.

34 ich may be beneficial in people with OSA and insomnia.

35 ystem and is prescribed for the treatment of insomnia.

36 hod for the treatment of chronic intractable insomnia.

37 production associated with acute and chronic insomnia.

38 tice guideline discouraged trazodone use for insomnia.

39 antly associated with lower odds of incident insomnia.

40 ally useful for people with OSA and comorbid insomnia.

41 each associated with higher odds of incident insomnia.

42 ts were anxiety (57.7%), stress (24.2%), and insomnia (10.2%).

43 placebo vs 18.17 [28.35] for ipilimumab) and insomnia (15.17 [22.53] vs 25.60 [29.19]).

44 After a mild TBI, 29% of patients have insomnia, 25% have sleep apnea, 28% have hypersomnia, an

45 ntly contributed to 86.9% of the variance in insomnia, 82.7% of the variance in daytime sleepiness an

46 of the high co-occurrence of depression and insomnia, a novel way to reduce the risk of escalating d

47 mnia (CBT-I) is the first-line treatment for insomnia; a key component of this intervention is restri

48 icantly positively related to improvement in insomnia after accounting for the effect of other depres

49 Outpatients with acute and chronic insomnia (aged 26-55 years; n=20 and 38, respectively) a

50 The most common AEs in F17464 group: insomnia, agitation, and increased triglycerides; worsen

51 Treatment-emergent adverse events (eg, insomnia, akathisia, worsening of schizophrenia, headach

52 , and demonstrate that VLPO lesion (model of insomnia) alters dynamical features of theta and delta r

53 strong positive genetic correlation between insomnia and alcohol use (rG = 0.56, se = 0.14, p < 0.00

54 Internet users (aged 18-64 years) with insomnia and depression symptoms, but who did not meet c

55 atory analyses suggest that older males with insomnia and elevated CRP may be particularly vulnerable

56 istress in postmenopausal women with chronic insomnia and explored associations between various facet

57 RQOL), there is insufficient data evaluating insomnia and HRQOL in children.

58 s, hopelessness, restlessness and agitation, insomnia and impulsiveness as measured by the STOP task.

59 e examined whether individuals with probable insomnia and individual insomnia symptoms had greater en

60 purpose of this study was to investigate if insomnia and insomnia-related sleep complaints are assoc

61 t common adverse reactions include headache, insomnia and nausea.

62 d two distinct SDs highly prevalent in PTSD; insomnia and nightmares.

63 Morningness is associated with insomnia and other sleep phenotypes; and is associated w

64 portant indicator for auxiliary diagnosis of insomnia and provide possible new therapeutic targets in

65 g the impact of anxiety and sleep hygiene on insomnia and related sleep complaints among collegiate s

66 has been demonstrated to be associated with insomnia and sleep disturbances that affect perception o

67 Clinical signs of insomnia and sleep-disordered breathing are common in mi

68 nificant common genetic risk factors between insomnia and substance use.

69 lation in the BG as a neural correlate of PD insomnia and suggest a mechanism by which this disorder

70 This underscores the importance of treating insomnia and suggests that laboratory sleep deprivation

71 In both the individuals with sleep-onset insomnia and the age-matched normal sleepers, lapses of

72 Insomnia and the inability to sleep affect people's heal

73 her sleep disorders (restless legs syndrome, insomnia) and sleep traits (duration, chronotype, accele

74 common cancer symptoms (depression, anxiety, insomnia) and whether these potential disparities modify

75 vomiting, nasopharyngitis, falls, headache, insomnia, and anxiety.

76 s associated with major depressive disorder, insomnia, and anxiety.

77 ytopenia, upper respiratory tract infection, insomnia, and decreased appetite (37.5% each).

78 se, the presence of ascites, encephalopathy, insomnia, and depression.

79 d by 10% of LDX participants were dry mouth, insomnia, and headache.

80 ctivity disorder (ADHD), alcohol dependence, insomnia, and heavy smoking are positively correlated.

81 topy, fatigue, excessive daytime sleepiness, insomnia, and only 0 to 3 nights of sufficient sleep had

82 key brain areas and cell types implicated in insomnia, and provide new treatment targets.

83 verse events were fatigue, nausea, headache, insomnia, and rash.

84 65-year-olds with major depressive disorder, insomnia, and suicidal ideation.

85 eritable phenotype frequently accompanied by insomnia, anxiety, and depression.

86 f sleep architecture, and the development of insomnia are ubiquitous in AUD and also map onto the thr

87 ance in individuals with chronic sleep-onset insomnia as compared to healthy normal controls.

88 ive genetic correlations with depression and insomnia as well as coronary artery disease, mirroring f

89 ts, vegetables, dairy products) with odds of insomnia at baseline (between 1994 and 1998; n = 77,860)

90 Purpose Cognitive behavioral therapy for insomnia (CBT-I) and Tai Chi Chih (TCC), a movement medi

91 Although cognitive behavior therapy for insomnia (CBT-I) has been established as the first-line

92 Cognitive behavioral therapy for insomnia (CBT-I) is the first-line treatment for insomni

93 treated by cognitive behavioral therapy for insomnia (CBT-I).

94 targeted both receptors for the treatment of insomnia, circadian rhythm and mood disorders, and cance

95 bance, as characterised either by reports of insomnia complaints with daytime consequences, dissatisf

96 inflammatory biology dynamics; the impact of insomnia complaints, extremes of sleep duration, and exp

97 pathways, tissue and cell types involved in insomnia complaints.

98 The degree of insomnia correlates with PD severity and it responds to

99 Thus, persons with sleep-onset insomnia could be at increased risk of performance impai

100 Insomnia, daytime functioning, and fatigue test scores d

101 Yet, only 3.4% of the women reported an insomnia diagnosis and 3.0% reported a sleep apnea diagn

102 common treatment-related adverse events were insomnia, diarrhoea, nausea, and dizziness.

103 assessing and managing patients with chronic insomnia disorder and obstructive sleep apnea (OSA).

104 , circadian rhythm sleep-wake disorders, and insomnia disorder are common conditions after SCI but re

105 = 31) or did not meet (n = 73) criteria for insomnia disorder as assessed by the Structured Clinical

106 recommendations on the management of chronic insomnia disorder in adults.

107 Adults (<=64 years) with insomnia disorder were randomized (1:1:1:1:1:1) to recei

108 diagnosis and assessment of OSA and chronic insomnia disorder, treatment and management of OSA, and

109 eep quality or quantity, or the diagnosis of insomnia disorder.

110 OSA, and treatment and management of chronic insomnia disorder.

111 vioral interventions are frequently used for insomnia disorder.

112 of MT(1) in complex with four agonists: the insomnia drug ramelteon(11), two melatonin analogues, an

113 sis of lemborexant, a recently approved anti-insomnia drug.

114 Zolpidem-CR had a robust anti-insomnia effect, especially in patients with the most se

115 Postmenopausal women with chronic insomnia endorse high rates of sexual distress.

116 irst time investigated (1) the prevalence of insomnia, excessive daytime sleepiness, anxiety and depr

117 Insomnia, fatigue and appetite changes had lower central

118 The most common adverse events (AEs) were insomnia, fatigue, and headache.

119 , familial CJD (gCJD) n = 17, fatal familial insomnia (FFI) n = 9, Gerstmann-Straussler-Scheinker syn

120 well as lab tests in Chinese fatal familial insomnia (FFI) subjects.

121 Individuals with primary insomnia frequently report cognitive impairment as a nex

122 Studying insomnia from different angles as a transdiagnostic phen

123 considerably exacerbated in the sleep-onset insomnia group, which showed about twice as many lapses

124 results and summary statistics of two recent insomnia GWAS and 13 significant loci were identified.

125 nders were controlled for, men with probable insomnia had a mean higher consumption of 35.8 kcal/d (9

126 ent reported by individuals with sleep-onset insomnia has an objective performance component that is

127 e impairment objectively in individuals with insomnia have yielded mixed results, with evidence sugge

128 Present day research takes the view on insomnia, i.e., prolonged sleep latency, problems to mai

129 Four major sleep complaints in insomnia, ie, sleep onset problems, poor sleep quality,

130 s between subjects with and without probable insomnia in 2004 and also across categories for each ins

131 rmation to conduct a genome wide analysis of insomnia in a 18,055 patient cohort.

132 d hazardous drinking) and sleep duration and insomnia in a general population study of older adults (

133 Insomnia in children is associated with worsened HRQOL a

134 OR: 1.16; CI: 1.08, 1.25; P-trend < 0.0001) insomnia in fully adjusted models.

135 nts of, and primary preventive measures for, insomnia in postmenopausal women.

136 hat high-GI diets could be a risk factor for insomnia in postmenopausal women.

137 is noninferior to CBT-I for the treatment of insomnia in survivors of breast cancer.

138 es and 47,610 controls), physician-diagnosed insomnia in the Partners Biobank (n = 2,217 cases and 14

139 sed, automated CBT-I intervention to improve insomnia in the short term (9 weeks) and long term (1 ye

140 leep phase disorder (DSPD), a common form of insomnia in which sleep episodes are shifted to later ti

141 group, and 18 in the opicapone 50 mg group), insomnia (in one, seven, two, seven, and seven patients,

142 Sleep disturbances including insomnia independently contribute to risk of inflammator

143 , amyotrophic lateral sclerosis, depression, insomnia, intelligence, neuroticism, and schizophrenia).

144 f escalating depression might be to offer an insomnia intervention.

145 It provides strong evidence that insomnia is a causal factor in the occurrence of psychot

146 Insomnia is a common disorder linked with adverse long-t

147 Fatal familial insomnia is a rare disease caused by a D178N mutation in

148 Insomnia is a well-established risk factor for late-life

149 Insomnia is also a common comorbidity across psychiatric

150 Probable insomnia is associated with higher intakes of total ener

151 Insomnia is associated with increased risk for suicide.

152 ent study was to determine whether late-life insomnia is associated with reduced motivation and reduc

153 Late-life insomnia is associated with reduced motivation and sensi

154 Insomnia is associated with several adverse health outco

155 Insomnia is common in children, and is associated with d

156 Insomnia is common in postmenopausal women, and disturbe

157 e that refined carbohydrates have on risk of insomnia is likely commensurate with their relative cont

158 The association of alcohol dependence with insomnia is likely to be bidirectional in nature.

159 Although adult insomnia is linked to worsened health-related quality of

160 Insomnia is one of the most prevalent and burdensome men

161 Insomnia is the most common sleep disorder among adults,

162 Insomnia is the second most prevalent mental disorder, w

163 patients were sleep disturbances, including insomnia, laryngeal stridor, sleep breath disturbance, a

164 We aimed to determine whether treating insomnia leads to a reduction in paranoia and hallucinat

165 Thus, postmenopausal women with insomnia may be especially vulnerable to developing sexu

166 sitivity for monetary reward, which suggests insomnia may confer risk for late-life depression by dys

167 It has been suggested that persons with insomnia may have latent performance deficits for which

168 ing research is testing whether treatment of insomnia may reduce suicidality in adults with depressio

169 95% CI 7-30), dyspnea (MD 15, 95% CI 2-27), insomnia (MD 20, 95% CI 8-32), and eating problems (MD 1

170 uded sleep disturbances (eg, sleep apnea and insomnia), mental health status (eg, posttraumatic stres

171 ropenia (n=2 [5%]), hypertension (n=2 [5%]), insomnia (n=1 [2%]), tinnitus and dizziness (n=1 [2%]),

172 3755 participants to receive digital CBT for insomnia (n=1891) or usual practice (n=1864).

173 Poverty-related sleep issues are linked to insomnia, obesity-related disparities center on sleep-re

174 associated with other sleep disorders (e.g., insomnia, obstructive sleep apnea, and parasomnias).

175 In addition, sleep disorders such as insomnia, obstructive sleep apnea, rapid eye movement sl

176 ommon adverse events, including headache and insomnia, occurred at the time of drug initiation and we

177 orting a new medical condition (intermittent insomnia odds ratio 5.9 [95% CI 1.3-26.7, p = 0.04], per

178 5.9 [95% CI 1.3-26.7, p = 0.04], persistent insomnia odds ratio 8 [95% CI 2.3-27.7, p = 0.001]).

179 ndomization identified the causal effects of insomnia on depression, diabetes, and cardiovascular dis

180 n; and the influence of sleep complaints and insomnia on inflammaging and molecular processes of cell

181 sults suggest that interventions that target insomnia or deficits in reward processing may mitigate t

182 Infection, hypotension, hyponatremia, insomnia or stress, and benzodiazepine use were higher d

183 ital cognitive behavioural therapy (CBT) for insomnia or usual care, and the research team were maske

184 m based on cognitive behavioural therapy for insomnia, or HealthWatch, an interactive, attention-matc

185 The primary outcome measures were for insomnia, paranoia, and hallucinatory experiences.

186 The gut microbiomes of insomnia patients compared with healthy controls were ch

187 signature bacteria for distinguishing acute insomnia patients from healthy controls, while Faecaliba

188 ignature bacteria for distinguishing chronic insomnia patients from healthy controls.

189 nges and increased inflammatory cytokines in insomnia patients.

190 Psychophysiological insomnia (PI) includes arousal to sleep-related stimuli

191 oad would be associated with greater odds of insomnia prevalence and incidence.

192 is: can the early and adequate treatment of insomnia prevent depression?

193 Controlling for anxiety or insomnia produced similar results.

194 to receive SHUTi, a 6 week, modular, online insomnia program based on cognitive behavioural therapy

195 aimed to assess whether an online self-help insomnia program could reduce depression symptoms.

196 for interview to assess quality of sleep and Insomnia (PSQI score >5).

197 Acute/chronic insomnia-related signature bacteria also showed correlat

198 his study was to investigate if insomnia and insomnia-related sleep complaints are associated with an

199 All four insomnia-related sleep complaints were associated with i

200 Insomnia-related stress dysregulation was similarly asso

201 ets of sexual health, insomnia symptoms, and insomnia-related stress dysregulation.

202 Insomnia remains under-diagnosed and poorly treated desp

203 For secondary outcomes, insomnia remission was 46.2% and 37.9% in CBT-I and TCC,

204 sodes of headache and 47% of the episodes of insomnia resolved within 7 days.

205 predictive value of sex, daytime somnolence, insomnia, restless legs syndrome, sleep apnoea, urinary

206 genetic correlation of suicide attempt with insomnia (rg = 0.34-0.81) as well as several psychiatric

207 e Pittsburgh Sleep Quality Index, the Athens Insomnia Scale, and a sleep diary to capture general sub

208 Altogether, 303 adults with chronic insomnia self-referred to participate, of whom 151 (49.8

209 utcomes were self-reported online ratings of insomnia severity (Insomnia Severity Index) and online s

210 sk factors and working hours, as well as the Insomnia Severity Index (ISI), a validated instrument fo

211 by the Menopause Quality of Life (Men-QoL), Insomnia Severity Index (ISI), Self-Rating Anxiety Scale

212 for all variables, favoring the SHUTi group (Insomnia Severity Index [F3,1063 = 20.65, P < .001], sle

213 re maintained at the 1-year follow-up (SHUTi Insomnia Severity Index d = 2.32 [95% CI, 2.01-2.63], sl

214 emed treatment responders at 1 year based on Insomnia Severity Index data.

215 e was self-rated insomnia symptoms using the Insomnia Severity Index in a linear mixed-effects model.

216 ignificantly greater score reductions on the Insomnia Severity Index than at-risk patients given stan

217 eported online ratings of insomnia severity (Insomnia Severity Index) and online sleep diary-derived

218 3.7, p=0.001) and reduced insomnia symptoms (Insomnia Severity Index: 18.2+/-5.2 versus 12.8+/-7.0, p

219 Insomnia severity was associated with hyperarousal (beta

220 ants (n = 1,199) completed questionnaires on insomnia severity, hyperarousal, self-conscious emotiona

221 he phenotype determination of sporadic fatal insomnia (sFI) and a subtype of sporadic Creutzfeldt-Jak

222 Older adults with late-life insomnia showed reduced reward motivation 95% CI [-0.955

223 hypnotic drugs approved for the treatment of insomnia [sleep aids], attention-deficit/hyperactivity d

224 utcomes were clinician-assessed remission of insomnia; sleep quality; total sleep time, sleep onset l

225 stionnaires containing validated measures on insomnia, sleepiness, anxiety, depression and gaming add

226 in 2004 and also across categories for each insomnia symptom while adjusting for related covariates.

227 These findings suggest that insomnia symptomology, gut microbiota, and inflammation

228 (>=18 years), poor sleep quality (13.3%) and insomnia symptoms (9.6-19.4%) were more prevalent than s

229 /-3.3 versus 8.5+/-3.7, p=0.001) and reduced insomnia symptoms (Insomnia Severity Index: 18.2+/-5.2 v

230 We discover loci associated with insomnia symptoms (near MEIS1, TMEM132E, CYCL1 and TGFBI

231 ociated with 37% increased odds of new-onset insomnia symptoms (odds ratio = 1.37, 95% confidence int

232 4.5 +/- 7.1 years of age) with assessment of insomnia symptoms (restlessness, difficulty falling asle

233 was found for a possible causal link between insomnia symptoms and coronary artery disease, depressiv

234 on analyses of self-reported sleep duration, insomnia symptoms and excessive daytime sleepiness in th

235 ), higher evening salivary cortisol, greater insomnia symptoms and greater sleep variability compared

236 d genetic factors was found between frequent insomnia symptoms and restless legs syndrome, aging, and

237 Poverty was uniquely related to increased insomnia symptoms and trouble sleeping due to bad dreams

238 Insomnia symptoms are associated with vulnerability to a

239 n-based study of women in the United States, insomnia symptoms are implicated in accelerated aging.

240 Among those without insomnia symptoms at time 1, race-specific job discrimin

241 iduals with probable insomnia and individual insomnia symptoms had greater energy intake and a lower

242 el non-pharmacological device (BioBoosti) on insomnia symptoms in adults.

243 and confirmed their effects on self-reported insomnia symptoms in the HUNT Study (n = 14,923 cases an

244 Here we identified 57 loci for self-reported insomnia symptoms in the UK Biobank (n = 453,379) and co

245 ger duration relative to questionnaires, and insomnia symptoms may contribute to greater perceived di

246 d linear mixed effects models tested whether insomnia symptoms or sleep apnea were associated with di

247 The primary outcome was self-rated insomnia symptoms using the Insomnia Severity Index in a

248 TST was similar across countries, but insomnia symptoms were 1.5-2.9 times higher in the Unite

249 Insomnia symptoms were also associated with more late di

250 erns were measured with wrist actigraphy and insomnia symptoms were assessed subjectively.

251 Insomnia symptoms were associated with a 17 min longer d

252 Insomnia symptoms were largely associated with poor sexu

253 Insomnia symptoms were most frequent in people spending

254 Insomnia symptoms were related to advanced epigenetic ag

255 tive sleep measures assessing sleep quality, insomnia symptoms, and daytime sleepiness.

256 ons between various facets of sexual health, insomnia symptoms, and insomnia-related stress dysregula

257 l participant characteristics: reporting any insomnia symptoms, having sleep apnea, sex, body mass in

258 For individual insomnia symptoms, nonrestorative sleep and a difficulty

259 BioBoosti use yielded an improvement in insomnia symptoms.

260 especially in patients with the most severe insomnia symptoms.

261 i Chih (TCC), a movement meditation, improve insomnia symptoms.

262 ople in many societies and the prevalence of insomnia tends to increase with age, therefore this grou

263 nt cohort of patients with combined ADHD and insomnia that 8 of 62 patients and 0 of 369 controls car

264 Of these, the most common is insomnia, the difficulty to initiate and maintain sleep.

265 tion for the millions of adults with chronic insomnia, there is a paucity of trained clinicians to de

266 l ideation in all depressed outpatients with insomnia, they suggest that coprescription of a hypnotic

267 d the potential of interventions that target insomnia to reverse inflammation, are also reviewed.

268 Online cognitive behaviour therapy for insomnia treatment is a practical and effective way to r

269 The proportion of participants who showed insomnia treatment response at 15 months was 43.7% and 4

270 Primary outcome was insomnia treatment response-that is, marked clinical imp

271 Reducing Suicidal Ideation Through Insomnia Treatment was an 8-week three-site double-blind

272 aumatic Stress Disorder (PTSD) patients with insomnia under a yoga training regime.

273 Patients with chronic intractable insomnia undergoing PCSL (n=20) were evaluated with the

274 While the overall prevalence of insomnia was 26.6%, and little difference was found betw

275 < 0.001) and the estimates of prevalence of insomnia was 29.4% in the rural areas, significant highe

276 Insomnia was a mediator of change in paranoia and halluc

277 Insomnia was accompanied by the onset of nonrapid eye mo

278 Additionally, the presence of insomnia was associated with an increased risk of report

279 Persistent ICSD2-derived insomnia was associated with an increased risk of report

280 studies suggested that use of hypnotics for insomnia was associated with increased risk for dementia

281 In secondary exploratory analyses, late-life insomnia was associated with reduced motivation to a gre

282 Insomnia was associated with young age group (<=25 years

283 Insomnia was associated with younger age group (<=25 yea

284 lacebo acupuncture therapy designed to treat insomnia was implemented 18 times over the course of 8 w

285 ciation between these key characteristics of insomnia was mediated specifically by reduced overnight

286 th life stress, pain conditions, falls, age, insomnia, weight change, satisfaction, confiding in some

287 iprazine-treated patients were akathisia and insomnia; weight gain was slightly higher with cariprazi

288 ontrolled trial, 90 depression patients with insomnia were assigned into three different groups, rece

289 Symptoms of insomnia were associated with increased epigenetic age o

290 Subjects with chronic insomnia were instructed to hold the device in each hand

291 University students with insomnia were randomly assigned (1:1) with simple random

292 trolled Sleep (PCSL) for chronic intractable insomnia where the traditional analgesics in PCA were re

293 The strongest associations were found for insomnia, which significantly predicted suicide ideation

294 behavioural abnormalities, epilepsy, chronic insomnia, white matter changes on brain MRI, dysmorphic

295 hat involved survivors of breast cancer with insomnia who were recruited from the Los Angeles communi

296 t to determine whether targeted treatment of insomnia with controlled-release zolpidem (zolpidem-CR)

297 MPTP intoxication resulted in severe insomnia with delayed sleep onset, sleep fragmentation,

298 ogical processes and causal relationships of insomnia with disease are poorly understood.

299 reatment in 251 patients undergoing ICBT for insomnia with therapist guidance.

300 lpidem (zolpidem-CR) in suicidal adults with insomnia would provide a reduction in suicidal ideation